Quantitative 68Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with 177Lu-DOTATATE-Reference-Cited by-同舟云学术

Quantitative 68Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with 177Lu-DOTATATE

Published:2021-02-12 Issue:10 Volume:62 Page:1406-1414
ISSN:0161-5505
Container-title:Journal of Nuclear Medicine
language:en
Short-container-title:J Nucl Med

Author:

Ortega Claudia,Wong Rebecca K.S.,Schaefferkoetter Josh,Veit-Haibach Patrick,Myrehaug Sten,Juergens Rosalyn,Laidley David,Anconina Reut,Liu Amy,Metser Ur

Publisher

Society of Nuclear Medicine

Subject

Radiology, Nuclear Medicine and imaging

Reference31 articles.

1. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States;Dasari;JAMA Oncol.,2017

2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine Tumors Version 1.2013. https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine_blocks.pdf. Accessed September 17, 2021.

3. Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors

4. Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors;Bodei;Eur J Nucl Med Mol Imaging.,2016

5. Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate in Patients With Endocrine Gastroenteropancreatic Tumors

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dual Somatostatin Receptor/¹⁸F-FDG PET/CT Imaging in Patients with Well-Differentiated, Grade 2 and 3 Gastroenteropancreatic Neuroendocrine Tumors;Journal of Nuclear Medicine;2024-09-12

2. Deep Learning-powered CT-less Multi-tracer Organ Segmentation from PET Images: A solution for unreliable CT segmentation in PET/CT Imaging;2024-08-28

3. Retrospective evaluation of the predictive value of tumour burden at baseline [68 Ga]Ga-DOTA-TOC or -TATE PET/CT and tumour dosimetry in GEP-NET patients treated with PRRT;EJNMMI Reports;2024-08-08

4. Models using comprehensive, lesion-level, longitudinal [68Ga]Ga-DOTA-TATE PET-derived features lead to superior outcome prediction in neuroendocrine tumor patients treated with [177Lu]Lu-DOTA-TATE;European Journal of Nuclear Medicine and Molecular Imaging;2024-05-25

5. Defining the optimal segmentation method for measuring somatostatin receptor expressing tumor volume on 68Ga-DOTATATE positron emission tomography/computed tomography to predict prognosis in patients with gastroenteropancreatic neuroendocrine tumors;Nuclear Medicine Communications;2024-05-15